Medical cannabis use in the United States: a retrospective database study.
Anxiety
Chronic pain
Gender
Medical cannabis
Post-traumatic stress disorder
Journal
Journal of cannabis research
ISSN: 2522-5782
Titre abrégé: J Cannabis Res
Pays: England
ID NLM: 101752723
Informations de publication
Date de publication:
29 Sep 2020
29 Sep 2020
Historique:
received:
27
04
2020
accepted:
09
09
2020
entrez:
2
2
2021
pubmed:
3
2
2021
medline:
3
2
2021
Statut:
epublish
Résumé
Growing interest in the medicinal properties of cannabis has led to an increase in its use to treat medical conditions, and the establishment of state-specific medical cannabis programs. Despite medical cannabis being legal in 33 states and the District of Colombia, there remains a paucity of data characterizing the patients accessing medical cannabis programs. We retrospectively reviewed a registry with data from 33 medical cannabis evaluation clinics in the United States, owned and operated by CB2 Insights. Data were collected primarily by face-to-face interviews for patients seeking medical cannabis certification between November 18, 2018 and March 18, 2020. Patients were removed from the analysis if they did not have a valid date of birth, were less than 18, or did not have a primary medical condition reported; a total of 61,379 patients were included in the analysis. Data were summarized using descriptive statistics expressed as a mean (standard deviation (SD)) or median (interquartile range (IQR)) as appropriate for continuous variables, and number (percent) for categorical variables. Statistical tests performed across groups included t-tests, chi-squared tests and regression. The average age of patients was 45.5, 54.8% were male and the majority were Caucasian (87.5%). Female patients were significantly older than males (47.0 compared to 44.6). Most patients reported cannabis experience prior to seeking medical certification (66.9%). The top three mutually exclusive primary medical conditions reported were unspecified chronic pain (38.8%), anxiety (13.5%) and post-traumatic stress disorder (PTSD) (8.4%). The average number of comorbid conditions reported was 2.7, of which anxiety was the most common (28.3%). Females reported significantly more comorbid conditions than males (3.1 compared to 2.3). This retrospective study highlighted the range and number of conditions for which patients in the US seek medical cannabis. Rigorous clinical trials investigating the use of medical cannabis to treat pain conditions, anxiety, insomnia, depression and PTSD would benefit a large number of patients, many of whom use medical cannabis to treat multiple conditions.
Identifiants
pubmed: 33526110
doi: 10.1186/s42238-020-00038-w
pii: 10.1186/s42238-020-00038-w
pmc: PMC7819290
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
32Références
Front Pharmacol. 2018 Nov 13;9:1259
pubmed: 30542280
J Psychoactive Drugs. 2015 Jan-Mar;47(1):18-23
pubmed: 25715068
Medicines (Basel). 2018 Dec 23;6(1):
pubmed: 30583596
Cannabis Cannabinoid Res. 2016 Jun 01;1(1):131-138
pubmed: 28861489
Pharmacol Ther. 1997;74(2):129-80
pubmed: 9336020
Cannabis. 2019 Feb 9;2(1):53-65
pubmed: 30815638
Soc Sci Med. 1983;17(16):1107-23
pubmed: 6623118
Health Aff (Millwood). 2019 Feb;38(2):295-302
pubmed: 30715980
J Fam Pract. 2000 Feb;49(2):147-52
pubmed: 10718692
BMC Med. 2019 Nov 12;17(1):201
pubmed: 31711480
Am J Psychiatry. 1997 Dec;154(12):1641-7
pubmed: 9396940
Soc Sci Med. 2019 Jul;233:181-192
pubmed: 31207470
Soc Sci Med. 1999 Jan;48(1):89-98
pubmed: 10048840
Can J Physiol Pharmacol. 2017 Apr;95(4):311-327
pubmed: 28263083
Drug Alcohol Depend. 2016 Feb 1;159:72-9
pubmed: 26686277
Am J Drug Alcohol Abuse. 2014 Jan;40(1):23-30
pubmed: 24205805
Drugs. 2018 Nov;78(16):1665-1703
pubmed: 30374797
Nat Commun. 2019 Feb 8;10(1):666
pubmed: 30737381
Health Matrix. 1987 Summer;5(2):3-19
pubmed: 10283417
J Psychoactive Drugs. 2011 Apr-Jun;43(2):128-35
pubmed: 21858958
Curr Clin Pharmacol. 2016;11(2):110-7
pubmed: 27086601
Pharmacol Rev. 2010 Dec;62(4):588-631
pubmed: 21079038
J Addict Med. 2018 Jul/Aug;12(4):295-299
pubmed: 29664895
Annu Rev Clin Psychol. 2017 May 8;13:397-419
pubmed: 28482686
BMC Public Health. 2020 Feb 4;20(1):156
pubmed: 32013937
J AOAC Int. 2019 Mar 1;102(2):412-420
pubmed: 30139415